p53 Modulation as a Therapeutic Strategy in Gastrointestinal Stromal Tumors

The KIT-inhibitor imatinib mesylate (IM) has greatly improved the treatment of metastatic gastrointestinal stromal tumors (GIST). IM exhibits strong antiproliferative effects but fails to induce sufficient levels of apoptosis resulting in low pathologic complete remission rates and a high rate of se...

Descripción completa

Detalles Bibliográficos
Autores principales: Henze, Joern, Mühlenberg, Thomas, Simon, Susanne, Grabellus, Florian, Rubin, Brian, Taeger, Georg, Schuler, Martin, Treckmann, Juergen, Debiec-Rychter, Maria, Taguchi, Takahiro, Fletcher, Jonathan A., Bauer, Sebastian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2012
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3360609/
https://www.ncbi.nlm.nih.gov/pubmed/22662219
http://dx.doi.org/10.1371/journal.pone.0037776

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3360609/
https://www.ncbi.nlm.nih.gov/pubmed/22662219
http://dx.doi.org/10.1371/journal.pone.0037776

Ejemplares similares